Abstract:Abstract. Objective:. To compare the effects between carbetocin and oxytocin on reducing postpartum hemorrhage (PPH) after vaginal delivery in high risk pregnant women. Methods:. A prospective double-blinded randomized study was conducted in the Nanjing Drum Tower Hospital from March to May 2018. Women at or beyond 28 gestational weeks, cephalic presentation, 18–45 years old, and with at least one risk factor for PPH, were enrolled. Using a computer-generated randomization sequence, women were randomized to carbetocin group or oxytocin group which receive 100 μg intravenous infusion carbetocin or 10 IU intravenous infusion of oxytocin after anterior shoulder and before placental delivery. The primary outcome was the incidence of blood loss ≥500 mL within 24 hours postpartum. The secondary outcomes were amount of total blood loss, blood loss within 2 hours after delivery, the rate of blood loss ≥ 1 000 mL postpartum, need for a second-line uterotonics and interventions, blood transfusion, difference between hemoglobin before and 48 hours after delivery, adverse maternal events attributed to the trial medication. Hemodynamic status (blood pressure and pulse) was measured at 0 minutes, 30 minutes, 60 minutes, and 120 minutes after delivery. Results:. A total of 314 and 310 participants constituted the carbetocin and oxytocin groups, respectively. The baseline characteristics were comparable between the groups. The carbetocin group had similar rates of PPH (blood loss ≥500 mL) and rates of ≥1 000 mL PPH, (29.6% vs. 26.8%, P = 0.48) and (3.2% vs. 3.5%, P = 0.83), to the oxytocin group. The average amount of bleeding was (422.9 ± 241.4) mL in carbetocin group and (406.0 ± 257.5) mL in oxytocin group, which was no statistically significant difference (P = 0.40). Either the amount of blood loss within 2 hours ((55.5 ± 33.9) mL vs. (59.9 ± 48.7) mL) was no statistically significant difference (P = 0.19). The need for therapeutic uterotonics was 23.9% in carbetocin group and 23.5% in oxytocin group, which was also no statistically difference (P = 0.93). The rate of blood transfusion (P = 0.62) and hemoglobin change (P = 0.07) were not differ between the carbetocin and oxytocin groups. However, the rate of manually removing placenta was significantly different between two groups regarding the need for manually remove of placenta because of uterine bleeding in the third stage of labor (4 cases in carbetocin group vs. 13 cases in oxygen group), especially in those after oxytocin-induced or augmented labor (relative risk:3.39, 95% confidence interval: 1.09–10.52). After delivery, the blood pressure in the carbetocin group tend to be lower than that in the oxytocin group (P > 0.05), especially at 30 minutes postpartum (P < 0.05), while pulse tend to be simultaneously higher (P > 0.05). Conclusion:. Among women with high risk of PPH, intravenous carbetocin infusion did not better than oxytocin in the prevention of blood loss ≥500 mL after vaginal delivery.

Effect of combined administration of carboprost tromethamine and ergometrine on uterine atony-induced postpartum hemorrhage

Clinical Analysis of Tocolysis with Ritodrine Hydrochloride or Atosibanin Treatment of Threatened Preterm Labour

A Multicenter, Double-Blind, Randomized Controlled Clinical Trial Comparing Ergometrine with Oxytocin and Oxytocin Alone for Prevention of Postpartum Hemorrhage at Cesarean Section

[Multicenter, Randomized, Double-Blind, and Positive Drug-Controlled Clinical Trial on Prevention of Postpartum Hemorrhage after Vaginal Delivery with Ergometrine Maleate].

Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss Control in Patients Undergoing Cesarean Delivery: a Systematic Review and Meta-Analysis

Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section

Application of Carboprost Tromethamine in preventing postpartum hemorrhage of patient with pregnancy complicated with hysteromyoma

Side‐effects of Carbetocin to Prevent Postpartum Hemorrhage: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Effects of Carboprost Tromethamine Combined with Modified B-Lynch Sutura on Prognosis and Life Quality in Treatment of Patients with Refractory Uterine Inertia Postpartum Hemorrhage

Clinical observation of oxytocin combined with prostaglandins in prevention of postpartum hemorrhage of high-risk pregnancy puerperae with caesarean section

Comparison of Ergonovine Maleate and Oxytocin for Prevention of Postpartum Hemorrhage of High-Risk Parturient Women

Carboprost Tromethamine with Oxytocin in Placenta Previa and Hemorrhage: an Analysis on the Effect of Efficacy, Safety and Blood Loss

Effect of carbetocin combined with Bakri balloon tamponade on postpartum hemorrhage

Clinical Observation on Hemabate Combined with Misoprostol for Prevention and Treatment of Postpartum Hemorrhage

Clinical observation of the effects on prevention from postpartum hemorrhage after caesarean section by application of Hemabate combined with 10% of Calcium Gluconate and Oxytocin

Effectiveness and safety of carboxytocin versus oxytocin in preventing postpartum hemorrhage: A systematic review and meta-analysis

Misoprostol Versus Ergometrine‐oxytocin for Preventing Postpartum Haemorrhage: a Systematic Review and Meta‐analysis of Randomized Controlled Trials

Comparison of the Effectiveness and Safety of Carbetocin and Oxytocin for the Prevention of Postpartum Hemorrhage after Caesarean Section

Intravenous Administration of Carbetocin Versus Oxytocin for Preventing Postpartum Hemorrhage after Vaginal Delivery in High Risk Women: A Double-blind, Randomized Controlled Trial

Evaluation of Application Time and Effects of Carboprost Trometamol for Patient with Complete Placenta Praevia in Cesarean-Section

Preventing postpartum hemorrhage: A network meta-analysis on routes of administration of uterotonics